BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,055 filers reported holding BAXTER INTL INC in Q2 2022. The put-call ratio across all filers is 1.57 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,836 | -14.5% | 62,246 | -23.9% | 0.06% | -26.9% |
| Q1 2023 | $3,316 | -48.6% | 81,766 | -35.3% | 0.08% | -57.4% |
| Q4 2022 | $6,446 | -99.9% | 126,473 | -4.8% | 0.18% | -3.2% |
| Q3 2022 | $7,157,000 | +958.7% | 132,875 | +1425.0% | 0.19% | +1081.2% |
| Q1 2022 | $676,000 | -97.5% | 8,713 | -98.7% | 0.02% | -98.7% |
| Q1 2016 | $27,331,000 | +7938.5% | 665,300 | +7375.3% | 1.19% | +5065.2% |
| Q4 2015 | $340,000 | -17.1% | 8,900 | +59.8% | 0.02% | +187.5% |
| Q1 2014 | $410,000 | +59.5% | 5,570 | +50.5% | 0.01% | +33.3% |
| Q4 2013 | $257,000 | -85.1% | 3,700 | -86.0% | 0.01% | -68.4% |
| Q3 2013 | $1,730,000 | -62.9% | 26,340 | -60.9% | 0.02% | -86.0% |
| Q2 2013 | $4,669,000 | – | 67,400 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |